Tag: option

Under the Option Agreement and assuming the 75% interest is earned, Tisdale will  issue Skyharbour 1,111,111 Tisdale shares upfront, fund exploration expenditures totaling CAD $10,500,000, and pay Skyharbour CAD $11,100,000 in cash of which $6,500,000 can be settled for shares in the capital of Tisdale (“Shares”) over the five-year earn-in period. Jordan Trimble, President and CEO of Skyharbour, stated: “We are very excited to have this new Option Agreement signed as we continue to execute on our business model by adding value to our project base in the Athabasca Basin through strategic partnerships and prospect generation, as well as focused mineral exploration at ... Read more

A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, providing patients with an additional treatment option. Approved in the US since 2015 and EU since 2017, Reagila is approved in over 52 countries for the treatment of schizophrenia in adults. Schizophrenia is a complex psychiatric disorder comprising a range of symptoms – positive symptoms include hallucinations and delusions, while negative symptoms include social withdrawal and apathy. Affecting some 90,000 Australians, schizophrenia is our most stigmatised and disabling mental illness, with life expectancy nearly 15 years below the general population. ... Read more

A new treatment for schizophrenia in adults, Reagila(R)(cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, 2021, providing patients with an additional treatment option.1Schizophrenia is a complex psychiatric disorder2 comprising a range of symptoms, including positive symptoms, such as hallucinations and delusions,6,7 and negative symptoms, such as social withdrawal and apathy.8,9 Reagila(R) – in-licensed by Seqirus, a wholly-owned subsidiary of CSL – is an atypical antipsychotic which indirectly targets two neurotransmitters in the brain – dopamine and serotonin.10 Neurotransmitters are considered the brain’s ‘chemical pathways’.11 Approved in the US since 2015, and EU since 2017, Reagila(R) is ... Read more